Inhibitors of the mitochondrial permeability transition reduce ammonia-induced cell swelling in cultured astrocytes.
Ammonia is the principal neurotoxin implicated in the pathogenesis of hepatic encephalopathy, and astrocytes are the neural cells predominantly affected in this condition. Astrocyte swelling (cytotoxic edema) represents a critical component of the brain edema in acute form of hepatic encephalopathy (acute liver failure, ALF). Although mechanisms of astrocyte swelling by ammonia are not completely understood, cultured astrocytes exposed to pathophysiological levels of ammonia develop the mitochondrial permeability transition (mPT), a process that was shown to result in astrocyte swelling. Cyclosporin A (CsA), a traditional inhibitor of the mPT, was previously shown to completely block ammonia-induced astrocyte swelling in culture. However, the efficacy of CsA to protect cytotoxic brain edema in ALF is problematic because it poorly crosses the blood-brain barrier, which is relatively intact in ALF. We therefore examined the effect of agents that block the mPT but are also known to cross the blood-brain barrier, including pyruvate, magnesium, minocycline, and trifluoperazine on the ammonia-induced mPT, as well as cell swelling. Cultured astrocytes exposed to ammonia for 24 hr displayed the mPT as demonstrated by a CsA-sensitive dissipation of the mitochondrial inner membrane potential. Pyruvate, minocycline, magnesium, and trifluoperazine significantly blocked the ammonia-induced mPT. Ammonia resulted in a significant increase in cell volume, which was blocked by the above-mentioned agents to a variable degree. A regression analysis indicated a high correlation between the effectiveness of reducing the mPT and cell swelling. Our data suggest that all these agents have therapeutic potential in mitigating brain edema in ALF.
Reddy
Pichili V B
PV
Department of Pathology, Miller School of Medicine, University of Miami, Miami, Florida 33101, USA.
Rama Rao
Kakulavarapu V
KV
Norenberg
Michael D
MD
D000641:Ammonia / Q000378:metabolism / Q000633:toxicity*; D000818:Animals; D001253:Astrocytes / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000378:metabolism; D001921:Brain / Q000378:metabolism / Q000503:physiopathology; D001929:Brain Edema / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology*; D048429:Cell Size / Q000187:drug effects*; D002478:Cells, Cultured; D016572:Cyclosporine / Q000494:pharmacology; D006501:Hepatic Encephalopathy / Q000150:complications / Q000378:metabolism* / Q000503:physiopathology; D022124:Hyperammonemia / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D008274:Magnesium / Q000494:pharmacology; D008911:Minocycline / Q000494:pharmacology; D033681:Mitochondrial Membrane Transport Proteins / Q000037:antagonists & inhibitors / Q000502:physiology*; D000083162:Mitochondrial Permeability Transition Pore; D019289:Pyruvic Acid / Q000494:pharmacology; D051381:Rats; D014268:Trifluoperazine / Q000494:pharmacology; D014882:Water-Electrolyte Balance / Q000187:drug effects / Q000502:physiology
D033681:Mitochondrial Membrane Transport Proteins; D000083162:Mitochondrial Permeability Transition Pore; D014268:Trifluoperazine; D000641:Ammonia; D016572:Cyclosporine; D019289:Pyruvic Acid; D008911:Minocycline; D008274:Magnesium